Assess the exact arrangement—not a supplier’s brand name or an entire clinic network at once. For this assessment, distinguish three operating models:
| Model being assessed | Focus of this assessment |
|---|---|
| Purchasing clinic stock | Product and account eligibility, purchasing terms, receiving, storage, traceability and permitted use |
| Appointing a dispensing partner | Pharmacy identity, destination-state permissions, prescription fulfilment, patient support and reporting |
| Facilitating patient access | Programme eligibility, prescribing workflow, patient payment, communications and exception handling |
Complete a separate assessment when the supplier, facility, product, legal pathway or state coverage differs materially. Do not average a well-documented arrangement with an unresolved one.
Which regulatory assumptions must not be carried forward?
FDA’s April 1, 2026 clarification states that semaglutide and tirzepatide do not appear on its drug-shortage list or 503B bulks list. It also explains that patient-specific prescribing and restrictions on essentially copying commercially available drugs are separate conditions; adding B12 is not an automatic exemption. Treat this as dated source evidence, and refresh the relevant records before commitment. (fda.gov)
FDA announced a proposal, rather than a final determination, on April 30, 2026 to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list. Do not represent that announcement as a final rule or as permission to compound while a proposal is considered. This research is not a comprehensive litigation or docket-status opinion. (fda.gov)
FDA also cautions against describing compounded medicines as FDA-approved generics or claiming that a pharmacy or outsourcing facility is FDA-approved. Those assertions should not substitute for product-specific diligence. (fda.gov)
Explore the table row by row
A working view of the research
Purchasing clinic stock
- Focus of this assessment
- Product and account eligibility, purchasing terms, receiving, storage, traceability and permitted use
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- fda.gov · Source 2 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- fda.gov · Source 3 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs